EHA 2022 | First-line treatment selection in myelofibrosis
Aaron Gerds, MD, MS, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, discusses the optimal approach to the management of patients with myelofibrosis (MF) in the first-line setting. For patients with anemia, Dr Gerds recommends using erythropoietin stimulating agents (ESAs), luspatercept, or danazol, while patients whose main concern is spleen size and symptom burden should receive JAK inhibitors. In addition, patients with adequate hemoglobin levels and platelet counts should receive ruxolitinib while patients with low platelet counts should be treated with pacritinib. Moving forward, Dr Gerds discusses how other agents in development such as momelotinib and pelabresib will fit in the treatment algorithm of MF. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consulting or Advisory Role – Abbvie; Bristol-Myers Squibb; Constellation Pharmaceuticals; CTI BioPharma Corp; Novartis; PharmaEssentia; Sierra Oncology
